{"id":2250,"date":"2026-06-10T12:00:00","date_gmt":"2026-06-10T15:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2250"},"modified":"2026-06-10T12:00:00","modified_gmt":"2026-06-10T15:00:00","slug":"rss-clinica-medicina-dermatologia-clinica-psoriase-atopica-vitiligo-jak-topico-biologicos","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-dermatologia-clinica-psoriase-atopica-vitiligo-jak-topico-biologicos\/","title":{"rendered":"RSS dermato: psor\u00edase, at\u00f3pica, JAK, biol\u00f3g"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de dermatologia cl\u00ednica que reduzem RSS a descarte de gaze e luva<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de dermatologia cl\u00ednica<\/strong> + psor\u00edase placa+gutata+pustular+eritrod\u00e9rmica+inversa + PASI score<\/strong> + dermatite at\u00f3pica DA + EASI score + JAK t\u00f3pico delgocitinib + sist\u00eamico abrocitinib+upadacitinib + biol\u00f3gicos dupilumab+tralokinumab+lebrikizumab+nemolizumab<\/strong> + vitiligo segmentar+n\u00e3o-segmentar + ruxolitinib t\u00f3pico Opzelura + JAK sist\u00eamico<\/strong> + alopecia areata baricitinib+ritlecitinib+deuruxolitinib<\/strong> + HS hidradenite supurativa + adalimumab+secukinumab+bimekizumab + spesolimab pustular<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (sangue venoso + bi\u00f3psia pele 4mm punch+5mm punch+excisional + les\u00e3o suspeita melanoma+CBC+CEC+queratose act\u00ednica) + Grupo A2 (escarro condi\u00e7\u00f5es associadas IL-17\/23 + cultura microbiol\u00f3gica) + Grupo B (ICS t\u00f3pico+TCI+vitamina D an\u00e1logos+retinoide t\u00f3pico+JAK t\u00f3pico+sist\u00eamico+biol\u00f3gico anti-TNF+anti-IL-17+anti-IL-23+anti-IL-4R\u03b1+anti-IL-13+anti-IL-31+anti-IL-36 Lista B\/C5) + Grupo E (perfuro pen+seringa+agulha bi\u00f3psia 4mm+5mm punch+laser CO2+Q-switched). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze derma<\/strong> + ignoram especificidades dermatol\u00f3gicas + biol\u00f3gicos+JAK<\/strong> + subdimensionam Lista C5 imuno+JAK<\/strong> + perdem rastreabilidade biol\u00f3gico<\/strong>. A realidade \u00e9 exatamente o oposto. RSS dermato opera em 5 fluxos dermatol\u00f3gicos<\/strong> \u2014 psor\u00edase (PASI+anti-IL-17+IL-23+IL-36+JAK), DA (EASI+dupilumab+tralokinumab+lebrikizumab+nemolizumab+JAK abrocitinib+upadacitinib+JAK t\u00f3pico delgocitinib+ruxolitinib), vitiligo (ruxolitinib t\u00f3pico Opzelura+JAK), alopecia areata (baricitinib Olumiant+ritlecitinib Litfulo+deuruxolitinib Leqselvi), HS hidradenite (adalimumab+secukinumab+bimekizumab+spesolimab Spevigo).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de dermatologia cl\u00ednica, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos dermatol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS dermato tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
Psor\u00edase PASI+anti-IL<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAnti-IL-17+IL-23+IL-36<\/td>\n<\/tr>\n
DA EASI+dupilumab<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nIL-4R\u03b1+IL-13+JAK<\/td>\n<\/tr>\n
Vitiligo ruxol+JAK<\/td>\n1-3 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOpzelura+sist\u00eamico<\/td>\n<\/tr>\n
Alopecia areata JAK<\/td>\n1-3 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOlumiant+Litfulo+Leqselvi<\/td>\n<\/tr>\n
HS hidradenite<\/td>\n1,5-4 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAdalimumab+spesolimab<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 10,5-31 kg\/dia<\/strong> em cl\u00ednica dermato m\u00e9dia porte.<\/p>\n

Psor\u00edase PASI + anti-IL-17 + anti-IL-23 + anti-IL-36 + JAK: o est\u00e1gio inflamat\u00f3rio<\/h2>\n

A primeira camada \u00e9 psor\u00edase. Padr\u00e3o setorial inclui (a) psor\u00edase apresenta\u00e7\u00e3o<\/strong> com placa 90% + gutata + pustular GPP + eritrod\u00e9rmica + inversa + ungueal + escalpo + palmoplantar + PASI Psoriasis Area Severity Index 0-72 + DLQI+BSA Body Surface Area; (b) anti-IL-17 1L moderada-grave<\/strong> com secukinumab Cosentyx Novartis 300mg SC q4w + ixekizumab Taltz Lilly 80mg SC q4w + brodalumab Siliq Bausch anti-IL-17RA + bimekizumab Bimzelx UCB anti-IL-17A\/F dual; (c) anti-IL-23p19<\/strong> com risankizumab Skyrizi AbbVie 150mg SC q12w + guselkumab Tremfya Janssen 100mg SC q8w + tildrakizumab Ilumya Sun Pharma 100mg SC q12w + ustekinumab Stelara Janssen anti-IL-12\/23p40 90mg SC q12w + biossimilares; (d) anti-IL-36 GPP<\/strong> com spesolimab Spevigo Boehringer Ingelheim 900mg IV \u00fanica + Effisayil-1 GPP flare emerg\u00eancia aprova\u00e7\u00e3o FDA 2022; (e) JAK inhibitor<\/strong> com tofacitinib Xeljanz Pfizer JAK1\/3+upadacitinib Rinvoq AbbVie JAK1+deucravacitinib Sotyktu BMS TYK2 + apremilast Otezla Amgen PDE4 + retinoide t\u00f3pico+vitamina D an\u00e1logos calcipotriol+ICS t\u00f3pico Lista B\/C5.<\/p>\n

Cl\u00ednica com psor\u00edase madura escala PASI 90\/100 60-90% 16w<\/strong> + previne progress\u00e3o PsA<\/strong> + otimiza T2T treat-to-target<\/strong>. Como discutimos no post sobre reumato<\/a>, psor\u00edase \u00e9 base.<\/p>\n

DA + dupilumab + tralokinumab + lebrikizumab + nemolizumab + JAK: o est\u00e1gio T2-high at\u00f3pico<\/h2>\n

A segunda camada \u00e9 DA. Padr\u00e3o setorial inclui (a) DA dermatite at\u00f3pica diagn\u00f3stico<\/strong> com Hanifin-Rajka crit\u00e9rios + EASI Eczema Area Severity Index + IGA Investigator Global Assessment + Itch NRS Numerical Rating Scale + DLQI+POEM Patient Oriented Eczema Measure; (b) dupilumab Dupixent Sanofi\/Regeneron anti-IL-4R\u03b1 1L biologic<\/strong> 600mg loading + 300mg SC q2w + IL-4+IL-13 dual block + 1L pedi\u00e1trico \u22656m + atopic dermatitis + asma + EoE eosinophilic esophagitis + CRSwNP + prurigo nodularis + COPD; (c) tralokinumab Adbry Leo Pharma anti-IL-13<\/strong> 300mg SC q2w + ECZTRA-1\/2\/3; (d) lebrikizumab Ebglyss Lilly anti-IL-13<\/strong> 250mg SC q2w + ADvocate-1\/2 + ADhere; (e) nemolizumab Nemluvio Galderma anti-IL-31R\u03b1 prurigo nodularis+DA<\/strong> 30mg SC q4w + OLYMPIA + ARCADIA + JAK abrocitinib Cibinqo Pfizer JAK1+upadacitinib Rinvoq AbbVie JAK1 + JAK t\u00f3pico delgocitinib Corectim Japan+ruxolitinib Opzelura Incyte JAK1\/2 t\u00f3pico Lista C5.<\/p>\n

Cl\u00ednica com DA madura escala EASI-75 60-90% 16w<\/strong> + escala redu\u00e7\u00e3o prurido NRS<\/strong> + otimiza dupilumab+JAK adolescent+adulto+pedi<\/strong>. Conex\u00e3o com pneumo asma<\/a>.<\/p>\n

Vitiligo ruxolitinib + alopecia areata baricitinib + HS hidradenite spesolimab: o est\u00e1gio JAK+misc<\/h2>\n

A terceira camada \u00e9 vitiligo+alopecia+HS. Padr\u00e3o setorial inclui (a) vitiligo segmentar+n\u00e3o-segmentar<\/strong> com VASI Vitiligo Area Scoring Index + ruxolitinib Opzelura Incyte JAK1\/2 t\u00f3pico 1.5% BID + TRuE-V1\/V2 facial repigmenta\u00e7\u00e3o \u226575% F-VASI 30% w24 + UVB-NB narrowband + PUVA + transplante melanoc\u00edtico; (b) alopecia areata<\/strong> com SALT Severity Alopecia Tool + baricitinib Olumiant Lilly JAK1\/2 4mg PO QD BRAVE-AA1\/2 + ritlecitinib Litfulo Pfizer JAK3+TEC 50mg PO QD ALLEGRO + deuruxolitinib Leqselvi Sun Pharma JAK1\/2 8mg PO BID THRIVE-AA1\/2; (c) HS hidradenite supurativa<\/strong> com Hurley I-III + iHS4 score + adalimumab Humira AbbVie 40mg SC weekly PIONEER-1\/2 + secukinumab Cosentyx Novartis 300mg q4w SUNSHINE+SUNRISE + bimekizumab Bimzelx UCB BE HEARD; (d) GPP generalized pustular psoriasis<\/strong> spesolimab Spevigo Boehringer 900mg IV \u00fanica Effisayil-1 + imsidolimab AnaptysBio anti-IL-36R + xgeva-tronik; (e) outras condi\u00e7\u00f5es emergentes<\/strong> PN prurigo nodularis nemolizumab + EB epidermolysis bullosa beremagene geperpavec Vyjuvek Krystal gene therapy + ICA cutis laxa + Sj\u00f6gren+SSc cut\u00e2neo + LP lichen planus tofacitinib.<\/p>\n

Cl\u00ednica com vitiligo+alopecia+HS madura escala vitiligo F-VASI 30% w24<\/strong> + escala alopecia SALT 50<\/strong> + escala HS HiSCR 50% w12<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade dermato<\/h2>\n

Cl\u00ednica dermato b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 12.000-32.000<\/strong> mas perda de biol\u00f3gicos+JAK+vitiligo+HS.<\/p>\n

Cl\u00ednica dermato m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura psor\u00edase+DA+vitiligo.<\/p>\n

Cl\u00ednica dermato completa 5 fluxos.<\/strong> Psor\u00edase+DA+vitiligo+alopecia+HS + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura dermatol\u00f3gica + biol\u00f3gicos+JAK targeted PASI 90\/EASI 75 60-90% w16.<\/p>\n

Os tr\u00eas erros que aparecem em dermato<\/h2>\n

O primeiro \u00e9 a subdimensionamento biol\u00f3gicos+JAK Lista C5<\/strong>. Sem segrega\u00e7\u00e3o dupilumab+secukinumab+ixekizumab+bimekizumab+risankizumab+guselkumab+spesolimab+abrocitinib+upadacitinib+baricitinib+ritlecitinib+deuruxolitinib+ruxolitinib+nemolizumab+tralokinumab+lebrikizumab+brodalumab+ustekinumab + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada + impacto financeiro biol\u00f3gico R$ 30-180k\/ano\/paciente.<\/p>\n

O segundo \u00e9 a mistura psor\u00edase + DA + vitiligo + HS<\/strong>. Confunde rastreabilidade etiologia + impossibilita scoring PASI\/EASI\/VASI\/SALT\/Hurley + risco prescri\u00e7\u00e3o inadequada (anti-IL-17 vs anti-IL-13 vs JAK).<\/p>\n

O terceiro \u00e9 a falta de protocolo TB latente IGRA pr\u00e9-biol\u00f3gico<\/strong>. Sem QuantiFERON-TB Gold + IGRA + screening pr\u00e9-anti-TNF+anti-IL-17 = risco reativa\u00e7\u00e3o TB + zero rastreabilidade biosseguran\u00e7a + viola\u00e7\u00e3o NR-32.<\/p>\n

A regula\u00e7\u00e3o de RSS dermato no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com dermatologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBD Sociedade Brasileira Dermatologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS dermato 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a psor\u00edase placa+gutata+pustular GPP+eritrod\u00e9rmica+inversa+PASI+anti-IL-17 secukinumab Cosentyx+ixekizumab Taltz+brodalumab Siliq+bimekizumab Bimzelx+anti-IL-23 risankizumab Skyrizi+guselkumab Tremfya+tildrakizumab Ilumya+ustekinumab Stelara+anti-IL-36 spesolimab Spevigo Effisayil-1+JAK tofacitinib Xeljanz+upadacitinib Rinvoq+deucravacitinib Sotyktu BMS TYK2+apremilast Otezla Lista C5, DA EASI+IGA+POEM+dupilumab Dupixent Sanofi\/Regeneron anti-IL-4R\u03b1+tralokinumab Adbry Leo+lebrikizumab Ebglyss Lilly+nemolizumab Nemluvio Galderma anti-IL-31R\u03b1+abrocitinib Cibinqo+upadacitinib JAK1+JAK t\u00f3pico delgocitinib Corectim+ruxolitinib Opzelura Incyte, vitiligo VASI+ruxolitinib Opzelura t\u00f3pico TRuE-V1\/V2+UVB-NB+transplante melanoc\u00edtico+JAK sist\u00eamico, alopecia areata SALT+baricitinib Olumiant Lilly BRAVE-AA+ritlecitinib Litfulo Pfizer ALLEGRO+deuruxolitinib Leqselvi Sun Pharma THRIVE-AA, HS Hurley I-III+iHS4+adalimumab Humira PIONEER+secukinumab SUNSHINE+SUNRISE+bimekizumab BE HEARD+spesolimab GPP+nemolizumab PN+beremagene Vyjuvek Krystal gene therapy EB epidermolysis bullosa.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS dermato: psor\u00edase + at\u00f3pica + vitiligo + JAK + biol\u00f3gicos. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2249,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3084,2563,801,2770],"class_list":["post-2250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-atopica","tag-biologicos","tag-dermatologia","tag-psoriase"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2250"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2250\/revisions"}],"predecessor-version":[{"id":4348,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2250\/revisions\/4348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2249"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}